Berlin suspends vaccinations with AstraZeneca for women under 60
The state of Berlin is suspending the corona vaccinations with the vaccine from the manufacturer Astrazeneca for people under 60 years of age.
DAs a precautionary measure, the State of Berlin is suspending corona vaccinations with the active ingredient from the manufacturer Astrazeneca for women under 60 years of age. Berlin Health Senator Dilek Kalayci (SPD) announced this on Tuesday and referred to new data on side effects. She called this a “precautionary measure”. Corresponding appointments in vaccination centers will be canceled for the time being, according to Kalayci. The state now wants to wait for the deliberations at the federal level and statements from experts such as the Paul Ehrlich Institute.
The Charité and Vivantes clinics in the capital also stopped vaccinations until further notice with reference to cases of cerebral vein thrombosis in Germany. In the clinics, the suspension of vaccinations applies to women under 55 years of age. This applies above all to our own workforce. The Charité spokeswoman, Manuela Zingl, said on Tuesday: “From the Charité’s point of view, this step is necessary because further cerebral vein thromboses in women in Germany have become known in the meantime.”
In North Rhine-Westphalia, the heads of five of the six university clinics also spoke out in favor of a temporary stop to vaccinations of younger women with Astrazeneca. The risk of further deaths is too high, according to a joint letter to the federal and state health ministers, which is available to the German press agency.
The Berlin Charité spokeswoman Zingl emphasized that there were no complications in the Charité after vaccinations with Astrazeneca. However, this wants to act as a precaution and wait for final evaluations. During the pandemic, the Charité has given around 16,000 first and second vaccinations to its staff. “Astrazeneca accounted for the largest part of this,” said Zingl.
Germany – and numerous other countries – had temporarily suspended vaccination with the Astrazeneca substance in March because several cases of thrombosis (blood clots) in the cerebral veins were reported in relation to the vaccination. The vaccine is now being given again. The European Medicines Agency Ema had confirmed the safety of the vaccine, and the Standing Vaccination Commission in Germany had spoken out in favor of further use of the product.
The district of Euskirchen in North Rhine-Westphalia had already temporarily stopped the corona vaccination of women under 55 with the active ingredient from Astrazeneca on Monday. After a vaccinated woman (47) died last week, the district was now reported to have suspected “a serious illness” in a 28-year-old after being vaccinated with Astrazeneca. Both had suffered a sinus vein thrombosis, according to the district.
In Germany, 31 cases of sinus vein thrombosis after vaccination with the Astrazeneca vaccine are known, as the Paul Ehrlich Institute reported on Tuesday. By noon on Monday (March 29), 31 cases had been reported to the institute, and thrombocytopenia was also reported in 19 cases. In nine cases, the outcome was fatal, as the institute responsible for vaccine safety in Langen reported.
With the exception of two cases, according to the PEI, all reports concerned women aged 20 to 63 years. The two men were 36 and 57 years old. According to the Robert Koch Institute’s vaccination rate monitoring, 2.7 million first doses and 767 second doses of Astrazeneca were vaccinated up to and including Monday.
31 cases of sinus vein thrombosis after vaccination with AstraZeneca have now been reported to the Paul Ehrlich Institute. The institute announced this at the request of “Spiegel”. In 19 cases, a lack of blood platelets, a thrombocytopenia, was reported. Those affected died in nine cases. It is noticeable that men were only affected in two cases, a 36-year-old and a 57-year-old. According to the PEI, all other reports concern women aged 20 to 63 years. According to the Robert Koch Institute, around 2.7 million people in Germany have been vaccinated with Vaxzevria. According to vaccination monitoring data from eight federal states, women under the age of 70 make up two thirds of those who have been vaccinated so far.